Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LeMaitre Vascular (LMAT) has secured an exclusive distribution agreement for Aziyo Biologics' cardiovascular patches in the U.S. for three years, with an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year. The patches, including ProxiCor®, VasCure®, and Tyke®, utilize an extracellular matrix aimed at reducing inflammation and promoting healthy tissue formation. Aziyo reported $6.8 million in sales from these patches in 2022. LeMaitre anticipates a 50% gross margin from patch sales. President David Roberts expressed enthusiasm about enhancing the company's product offerings for vascular and cardiac surgeons. Further financial implications of this agreement will be detailed in LeMaitre’s Q1 2023 earnings call on May 2, 2023.
FAQ
What is the current stock price of Lemaitre Vasculr (LMAT)?
What is the market cap of Lemaitre Vasculr (LMAT)?
